Buy GLP-1-S (Semaglutide Analog) in the USA

Name: GLP1-S
Brand: BioInfinity Lab
SKU: GLP1-S
Availability: InStock

GLP-1-S is BioInfinity Lab's research-grade Semaglutide analog — a GLP-1 receptor agonist studied across the STEP, SUSTAIN, and SELECT trial families. ≥99% HPLC purity, third-party COA, same-day USA shipping.

GLP-1 receptor research analog≥99% HPLC puritySame-day NY shipping

Available sizes — GLP1-S

Choose a size to continue to the product page where you can add to cart and complete checkout.

Need full product specs, batch COA, or related products? View the full GLP1-S product page →

Why GLP-1-S is the foundational GLP research peptide

Semaglutide research literature is among the most extensive in modern metabolic biology. The STEP-1 trial (NEJM 2021, PMID 33567185) characterized weekly-administration outcomes in research populations with overweight or obesity; SUSTAIN-6 (NEJM 2016) reported cardiovascular endpoints in type-2 diabetes research; SELECT (NEJM 2023, PMID 34882832) examined cardiovascular research outcomes in non-diabetic populations.

GLP-1-S vs. GLP-2-T vs. GLP-3-R in research design

GLP-1-S is the single-agonist baseline. GLP-2-T adds GIP receptor activity. GLP-3-R adds both GIP and glucagon receptor activity. Researchers comparing the three should reference the SURPASS-2 publication for direct GLP-1-S vs GLP-2-T head-to-head data and the 2023 Retatrutide Phase 2 publication for GLP-3-R's reported activity profile.

Vial sizes

Available in lyophilized 2 mg, 5 mg, and 10 mg vials suitable for short, mid-length, and extended research protocols.

Storage and shipping

Lyophilized at −20 °C; reconstituted at 2–8 °C, typically used within 28 days. Same-day NY shipping on orders before 2 PM ET.

Research FAQ — GLP1-S

Frequently asked questions about this compound for laboratory researchers.

What is Semaglutide / GLP-1-S?+

Semaglutide is a GLP-1 receptor agonist research peptide. Published trial literature describes its pharmacology, glycemic effects in T2D research populations, and outcomes from the STEP and SUSTAIN trial families.

Cited: PMID 33567185, PMID 31185157

What does STEP-1 research data show?+

The STEP-1 publication (NEJM, 2021) describes once-weekly Semaglutide 2.4 mg versus placebo in research subjects with overweight or obesity over 68 weeks. The trial reports body-weight endpoints as its primary outcome.

Cited: PMID 33567185

How is Semaglutide dosed in published research?+

Published trial protocols administer Semaglutide once weekly via subcutaneous injection. Dose-titration schedules from 0.25 mg up to 2.4 mg are commonly reported. Refer to the cited literature and your IRB protocol.

Cited: PMID 33567185

How is Semaglutide stored?+

Lyophilized Semaglutide stores at −20 °C protected from light. Reconstituted solution is refrigerated at 2–8 °C and typically used within 28 days. Refer to the product COA.

Published research references

Peer-reviewed literature relevant to GLP1-S research. Linked PubMed IDs open the original source.

[1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — N Engl J Med (2021) · PMID 33567185
[2]Semaglutide and cardiovascular outcomes in obesity without diabetes — N Engl J Med (2023) · PMID 34882832
[3]Effect of Subcutaneous Semaglutide vs Placebo on Cardiovascular Outcomes (SUSTAIN-6) — N Engl J Med (2016) · PMID 31185157

Reviewed by the BioInfinity Research Team

Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Order GLP1-S from BioInfinity Lab

Same-day shipping from New York, ≥99% HPLC-verified purity, and a third-party COA on every lot.

Buy GLP1-S now

For laboratory research use only. Not for human or veterinary use.